159 results on '"Anargyrou, Konstantinos"'
Search Results
2. Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study
3. Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization
4. A prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation
5. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
6. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
7. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: Results from the Hellenic Dendritic Cell Leukemia Study Group
8. Incorporating novel agents in the treatment of myelodysplastic syndromes
9. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
10. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
11. Detection of CD55- and/or CD59-Deficient Red Cell Populations in Patients With Plasma Cell Dyscrasias
12. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents
13. Low bone mineral density and high bone turnover in patients with Non-Hodgkin's Lymphoma (NHL) who receive frontline therapy: results of a multicenter prospective study
14. Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study
15. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis
16. Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy
17. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis
18. Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study
19. Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study
20. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis
21. Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization
22. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
23. Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile Neutropenia
24. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents
25. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents
26. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents
27. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
28. Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab
29. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib
30. Novel anti-myeloma agents and angiogenesis
31. Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients
32. The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio
33. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents
34. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
35. Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents
36. Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study
37. Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study
38. First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).
39. CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of Immunohistochemical Markers and Poor Outcome.
40. Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients
41. Novel anti-myeloma agents and angiogenesis
42. Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab
43. The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).
44. High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.
45. The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.
46. The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.
47. Efficacy of Rituximab in Hairy Cell Leukemia.
48. Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN-α). The Importance of Maintenance.
49. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma
50. Adult T-Cell Leukemia/Lymphoma (ATLL): Report of Two Fully Documented Hellenic Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.